Back to results
US 2023/0416246 A1Published application
Compounds and uses thereof
AssigneeFoghorn Therapeutics Inc.
InventorsSabine K. RUPPEL, Zhaoxia YANG, Jason T. LOWE, Johannes H. VOIGT, Matthew NETHERTON
Life of this patent
Estimating the term…
Abstract
The present invention relates to compositions and methods for the treatment of BAF-related disorders, such as cancers and viral infections.
Claims19
(canceled)
A compound of Formula I:
- A-L-B Formula I
- or a pharmaceutically acceptable salt thereof, wherein:
- A has the structure of Formula IIIc:
- wherein:
- A1 is a bond between L and A;
- R4 is —CH3;
- R5 is H;
- R6a is H, halogen, cyano, or optionally substituted C1-C6 alkyl;
- R6b is H or —CH3;
- B has the structure of Formula AA0:
- wherein:
- A2 is a bond between B and L;
- v1 is 0, 1, 2, 3, 4, or 5;
- RA5 is H;
- JA is absent, O, optionally substituted amino, optionally substituted C1-C6 alkyl, or optionally substituted C1-C6 heteroalkyl;
- J is absent, optionally substituted C3-C10 carbocyclylene, optionally substituted C6-C10 arylene, optionally substituted C2-C9 heterocyclylene, or optionally substituted C2-C9 heteroarylene;
- L has the structure of Formula IIg:
- A1-(E1)-(F1)-(E3)n-(F2)o1-A2 Formula IIg
- wherein:
- each of n and o1 is, independently, 0 or 1;
- E1 is O, S, NRN, optionally substituted C1-10 alkylene, optionally substituted C2-10 alkenylene, optionally substituted C2-10 alkynylene, optionally substituted C2-C10 polyethylene glycol, or optionally substituted C1-10 heteroalkylene;
- E3 is optionally substituted C1-C6 alkylene, optionally substituted C1-C6 heteroalkylene, O, S, or NRN;
- each RN is, independently, H or methyl;
- and
- each of F1 and F2 is, independently, optionally substituted C2-9 heterocyclylene.
22 more elements
Dependencies are inferred from the claim text.